New drug interaction study launches for polycystic kidney disease treatment
NCT ID NCT07565441
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study tests how a new drug called JMKX003142 interacts with other common medications in 112 healthy Chinese adults. The drug is being developed for autosomal dominant polycystic kidney disease (ADPKD). Researchers will measure how the body processes JMKX003142 when taken with drugs like fluconazole, cyclosporine, and omeprazole. The results will help determine safe dosing for future patient studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JMKX003142 tablets
- What this could lead to
- If successful, this study will show how JMKX003142 interacts with other drugs, helping doctors choose safe doses for future ADPKD patients.
- What could go wrong
- This is an early Phase 1 trial in healthy people, not patients. It only checks drug interactions, not whether JMKX003142 works for ADPKD. Results may not predict real-world effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADPKD (AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.